الفهرس 
Evaluation of the results of intralesional bleomycin injection for yreatment of haemangioma and vascular malformation
ContentsOnly 14 pages are availabe for public view
 |  | from | 209 |  |  |
| | | from | 209 | | |
Abstract
Despite various treatments used, vascular anomalies in many cases present difficulties for physicians. Bleomycin is a cytotoxic antitumoral antibiotic, that has also been successfully used as intralesional injection treatment of treatment of Haemangioma and vascular malformations. The aim of the study is to evaluate the results of Intralesional Bleomycin Injection for treatment of Haemangioma and vascular malformation. Indications, limitations, adjustment of dose and results of treatment compared with control group for follow up receives no treatment (placebo group). Intralesional bleomycin injection (IBI) was effective and safe in treating vascular anomalies. Our analysis showed that the prefered dose of bleomycin treatment was not more than 1mg/kg or less. In our study, bleomycin was effective in Infantile Hemangiomas than venous malformations. Small and medium sized lesions have better response. Intralesional bleomycin injection (IBI) is a simple, practical and noninvasive method of treatment of vascular anomalies and can considered one of priorities in the treatment of Infantile Hemangiomas and small and medium sized venous malformations